Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
AbbVie has announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg [induction dose] and 15 […]
Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR)
Sapience Therapeutics, a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics […]
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
Telix Pharmaceuticals today announces the successful preclinical development of radiolabelled olaratumab, an antibody licensed from […]
WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) and its subsidiary […]
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
M2GEN Rebrands to Aster Insights
M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomic data to accelerate medical […]
Oxford Biotech Secures £13.2m to Develop World’s First Treatment for Rare, Incurable and Deadly Disease
SynaptixBio, whose aim is to develop a treatment for the rare genetic central nervous system […]
Function Oncology Launches to Transform the Future of Targeted Cancer Treatment with CRISPR
Function Oncology, a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to transform […]
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Amylyx Pharmaceuticals has announced that the first participant has been dosed in the HELIOS study, […]
Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies
The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more